Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: GlobeNewswire
NEWTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief Commercial Officer. In this role, Mr. Demaree will lead Karyopharm’s commercial strategy and operations, including the continued commercialization of oral XPOVIO® (selinexor), the Company’s first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound. “We are excited to welcome John to Karyopharm as we continue to execute on the commercialization of XPOVIO and look forward to key milestones in 2020 that could allow us to impact the lives of an increasing number of patients,” said Michael G. Kauffman, MD, Ph.D., Chief Executive Officer of Karyopharm. “John’s leadership and depth of experience launching and growing new oncology medicines will be essential as we continue to build our commercial strategy, team and capabilities for the future.” “Karyopharm is an exciting company with s
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerPR Newswire
- Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and ExpositionPR Newswire
- Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 11/5/24 - Beat
KPTI
Analyst Actions
- 11/1/24 - HC Wainwright
KPTI
Sec Filings
- 11/20/24 - Form 8-K
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- KPTI's page on the SEC website